Unravelling Cell Cycle and Ontogeny Transcriptional Heterogeneity in Hematopoietic Stem Cells through Integrated Single Cell RNA-Seq
Povinelli B. et al, (2017), BLOOD, 130
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Weber J. et al, (2017), N Engl J Med, 377, 1824 - 1835
Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials
Carvajal R. et al, (2017), JOURNAL FOR IMMUNOTHERAPY OF CANCER, 5
Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours.
Lyon PC. et al, (2017), Journal of Therapeutic Ultrasound, 5, 28 - 28
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM. et al, (2017), Eur J Cancer, 86, 115 - 124
QUALITY OF LIFE WITH WEEKLY, DOSE-DENSE VERSUS STANDARD CHEMOTHERAPY FOR OVARIAN CANCER IN THE ICON8 STUDY
Blagden SP. et al, (2017), INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 27, 1919 - 1919
QUALITY OF LIFE WITH WEEKLY, DOSE-DENSE VERSUS STANDARD CHEMOTHERAPY FOR OVARIAN CANCER IN THE ICON8 STUDY
Blagden SP. et al, (2017), INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 27, 14 - 14
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
Eyre TA. et al, (2017), British journal of haematology, 179, 471 - 479
Tasigna (nilotinib) in chronic myeloid leukemia treatment-free remission after nearly 2 years: an interview with Adam Mead
Mead A., (2017), FUTURE ONCOLOGY, 13, 2401 - 2404
Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator.
Vlachodimitropoulou E. et al, (2017), Blood, 130, 1923 - 1933
Societal preferences for adjuvant melanoma health states: UK and Australia.
Middleton MR. et al, (2017), BMC Cancer, 17, 689 - 689
Development of HM-PRO, a haematology specific Patient-Reported Outcome Measure: content validation
Goswami P. et al, (2017), QUALITY OF LIFE RESEARCH, 26, 130 - 130
Fluciclovine is a potential imaging biomarker of glutamine utilisation in breast cancer
Teoh EJ. et al, (2017), EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 44, S633 - S634
Mbd3/NuRD controls lymphoid cell fate and inhibits tumorigenesis by repressing a B cell transcriptional program.
Loughran SJ. et al, (2017), The Journal of Experimental Medicine, 214, 3085 - 3104
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Harrison CN. et al, (2017), Blood, 130, 1889 - 1897
Characterisation of the changing genomic landscape of metastatic melanoma using cell free DNA.
Cutts A. et al, (2017), NPJ genomic medicine, 2, 25 - 25
Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)
Weber J. et al, (2017), ANNALS OF ONCOLOGY, 28
Allogeneic Hematopoietic Cell Transplantation Outcomes After Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (CA209-039 and CheckMate 205)
Carlo-Stella C. et al, (2017), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 17, S326 - S327